Please assess the completion status of the following clinical trial:

Trial Title: Bupropion for Depression in ESRD Patients on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 30-70 yrs;~* have patent and non-infected arteriovenous fistula or graft;~* are receiving maintenance HD 3 times per week lasting for 3-4 hours;~* serum albumin of ≥ 3.2 g/dl, serum phosphate of \<6.5 mg/dl, and serum hemoglobin of ≥9 mg/dl in consecutive two blood tests as per the National Kidney Foundation Disease Outcomes Quality Initiative (NKF KDOQI) guidelines \[subjects failing screening due to blood test will be allowed to be re-screened in 30 days\];~* receiving stable or maintenance dose of iron or erythropoietin-stimulating agents, statins, angiotension receptor blockers and/or angiotension converting enzyme inhibitors, phosphate binders, vitamin D receptor analogs as these agents may influence cytokines proposed in the study;~* meet the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for MDD;~* have a Ham-D score \> 17~Exclusion Criteria:~* meet DSM-IV criteria for Bipolar Disorder or other psychotic disorder in the month prior to screening;~* are taking antidepressants, anti-anxiety medications, or hypnotics (including Zyban for smoking cessation);~* having failed to respond to or tolerate bupropion or fluoxetine in the past~* allergic to fluoxetine or bupropion~* known history of HIV/AIDS; No testing will be conducted for screening purposes~* known history of alcohol or drug abuse or dependence within the month prior to screening based on clinical records;~* history of myocardial infarction or heart failure within one month of screening or a history of seizures or stroke at any point;~* history of chronic liver disease and diagnosis of hepatic encephalopathy based on clinical records;~* currently diagnosed with cancer or receiving any cancer treatment;~* history of any infection within the last 2 weeks ;~* currently taking any antibiotics, anti-inflammatory, and immune-modulator agents;~* recorded noncompliance with dialysis schedules; and~* currently participating in clinical or behavioral intervention studies.~* recorded noncompliance with dialysis schedules; and~* currently participating in clinical or behavioral intervention studies

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fluoxetine (Type: ACTIVE_COMPARATOR): Fluoxetine up to 20 mg orally daily for 12 weeks. Flexible dosing between a minimum of 10 mg daily and 20 mg daily as tolerated.
- Bupropion (Type: EXPERIMENTAL): Bupropion sustained release (SR) 150 mg orally twice per week

Based on this trial design, predict the completion outcome and termination type (if applicable).